RHHBF:OTCQX-Roche Holding Ltd (USD)

COMMON STOCK | Drug Manufacturers - General | OTCQX Marketplace

Last Closing

USD 259

Change

0.00 (0.00)%

Market Cap

USD 219.37B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 240.18B
NVSEF Novartis AG

N/A

USD 208.10B
RHHBY Roche Holding Ltd ADR

N/A

USD 202.85B
RHHVF Roche Holding AG Participation

N/A

USD 202.50B
SNYNF Sanofi

N/A

USD 127.07B
GLAXF GSK plc

N/A

USD 92.19B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 66.43B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 66.43B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 53.36B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 52.77B

ETFs Containing RHHBF

FLDM:CA 2.00 % 0.44 %

N/A

N/A
DPK 0.00 % 0.96 %

N/A

N/A
EFAV 0.00 % 0.20 %

N/A

N/A
EFO ProShares Ultra MSCI EAFE 0.00 % 0.95 %

N/A

USD 0.01B
EFU ProShares UltraShort MSCI.. 0.00 % 0.95 %

N/A

USD 0.84M
EFZ ProShares Short MSCI EAFE 0.00 % 0.95 %

N/A

USD 0.02B
EPV ProShares UltraShort FTSE.. 0.00 % 0.95 %

N/A

USD 0.02B
PDEV 0.00 % 0.00 %

N/A

N/A
UPV ProShares Ultra FTSE Euro.. 0.00 % 0.95 %

N/A

USD 4.91M
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

CAD 0.01B
VHYL:LSE Vanguard FTSE All-World H.. 0.00 % 0.00 %

N/A

USD 4.49B
MVAE:PA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTCQX Marketplace)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.72% 33% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.72% 32% F 27% F
Trailing 12 Months  
Capital Gain -23.82% 40% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.82% 36% F 39% F
Trailing 5 Years  
Capital Gain 0.52% 66% D+ 66% D+
Dividend Return 3.61% 13% F 11% F
Total Return 4.13% 63% D 63% D
Average Annual (5 Year Horizon)  
Capital Gain 2.28% 62% D 44% F
Dividend Return 2.85% 47% F 40% F
Total Return 0.57% 7% C- 20% F
Risk Return Profile  
Volatility (Standard Deviation) 19.20% 71% C- 88% B+
Risk Adjusted Return 14.85% 50% F 49% F
Market Capitalization 219.37B 92% A 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector